Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has announced the lineup of conferences it will be attending in October. The company will also be participating in these events, with its corporate and clinical presentations highlighting GNPX gene therapies designed to treat cancer and diabetes. The company is planning to attend the Dawson James Securities Annual Small Cap Growth Conference, the Immuno-Oncology Summit, the BIO Europe event and the LD Micro Main Event XV. Genprex executive vice president, general counsel and chief strategy officer Catherine Vaczy will be presenting at the Dawson James Conference, which is scheduled for Oct. 12, 2022, in Jupiter, Florida. Vaczy’s presentation will begin at 9 a.m. ET. and a replay of the presentation will be available on the company website. Genprex chief medical officer Mark Berger will be presenting at the two-day Immuno-Oncology Summit, which is scheduled for Oct. 12–14, 2022; the event will be held in Boston. Berger’s presentation is slated to begin at 3:45 p.m. ET on Oct. 12, and he will focus on Genprex’s REQORSA(TM) Gene Therapy in combination with immune checkpoint inhibitors. Genprex representatives will be available to meet with attendees at the BIO Europe gathering throughout the two-day event, which is scheduled from Oct. 24–26, 2022; the event will be held in Germany. Genprex chief financial officer Ryan Confer will be presenting at the LD Micro Main Event XV, which will be held in Los Angeles on Oct. 25–27, 2022. Confer’s presentation will begin at 3 p.m. PT on Oct. 26, 2022. Company officials will also be available to meet with attendees at each of the four events.
To view the full Dawson James Securities Annual Small Cap Growth Conference presentation, visit https://ibn.fm/ohaei
To view the full LD Micro Main Event XV presentation, visit https://ibn.fm/gpNuv
To view the full press release, visit https://ibn.fm/paYd4
About Genprex Inc.
Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, which currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its proprietary, nonviral ONCOPREX(R) Nanoparticle Delivery System, which the company believes is the first systemic, gene-therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is then taken up by tumor cells that express proteins that are deficient. The company’s lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”), with each of its clinical programs receiving a fast-track designation from the Food and Drug Administration, and small cell lung cancer. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (“AAV”) vector to deliver Pdx1 (“Pdx1”) and MafA (“MafA”) genes to the pancreas. In models of T1D, the genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. In T2D, where autoimmunity is not at play, it is believed that exhausted beta cells are also rejuvenated and replenished. For more information, please visit the company’s website at www.Genprex.com
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
